Literature DB >> 8324750

Nuclear matrix proteins in normal and breast cancer cells.

P S Khanuja1, J E Lehr, H D Soule, S K Gehani, A C Noto, S Choudhury, R Chen, K J Pienta.   

Abstract

The progression from normal breast epithelium to a malignant phenotype may depend on changes in genetic events as well as failure of host mechanisms. Intermediate biomarkers are needed to more effectively identify malignant progression as well as to develop the potential for more specific treatments and prevention strategies. The nuclear matrix is the RNA-protein network which forms the skeleton of the nucleus and participates in DNA organization as well as multiple cellular functions. Nuclear matrix proteins have been demonstrated to be tissue and cell type specific as well as to reflect the state of cell differentiation and/or transformation. We prepared nuclear matrices from normal and cancer breast tissue from 10 patients with infiltrating ductal carcinoma of the breast as well as the MCF-10 mortal, immortal, and transfected breast cell lines. Nuclear matrices derived from normal human breast tissue and tumor tissue share common nuclear matrix proteins as well as demonstrate specific changes which appear to occur with the acquisition of the cancer phenotype. The MCF-10 cell lines demonstrate a phenotype that is intermediate between the normal and cancer tissue. These data suggest that the nuclear matrix may be an important biomarker in the pathogenesis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324750

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Modulation of chromatin by MARs and MAR binding oncogenic transcription factor SMAR1.

Authors:  Kiran K Nakka; Samit Chattopadhyay
Journal:  Mol Cell Biochem       Date:  2009-10-03       Impact factor: 3.396

Review 2.  Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin.

Authors:  J R Davie
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

3.  Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells.

Authors:  Chun-Hong Zhao; Qi-Fu Li
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 4.  The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.

Authors:  S W Shelfo; M S Soloway
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Rethinking cell structure.

Authors:  S Penman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

6.  Tissue matrix protein expression in human osteoblasts, osteosarcoma tumors, and osteosarcoma cell lines.

Authors:  J Bidwell; R McCabe; B Rougraff; H Feister; E Fey; J Onyia; J Holden; J Hock
Journal:  Mol Biol Rep       Date:  1997-11       Impact factor: 2.316

7.  Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.

Authors:  Murat Lekili; Ercüment Sener; Mehmet Akif Demir; Gökhan Temeltaş; Talha Müezzinoğlu; Coşkun Büyüksu
Journal:  Urol Res       Date:  2003-12-19

Review 8.  Urinary markers in screening patients with hematuria.

Authors:  Edmund Chiong; Kris E Gaston; H Barton Grossman
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

9.  Nuclear matrix proteins in human colon cancer.

Authors:  S K Keesee; M D Meneghini; R P Szaro; Y J Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

Review 10.  Defining the role of NMP22 in bladder cancer surveillance.

Authors:  Carvell T Nguyen; J Stephen Jones
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.